Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children

Sponsor

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (Other)

Overall Status

Unknown status

CT.gov ID

NCT03984552

Collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico (Other)

502

Enrollment

Location

64.7

Anticipated Duration (Months)

7.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Antiretroviral therapy of the mother and of the newborn associated with alternative schemes of breastfeeding can reduce these transmission rates to 1%. The diagnosis of HIV infection in newborns is based on PCR for detection of viral genetic material, a procedure that is expensive and of complex logistics. Tests based on detection of antibodies are faster and cheaper but cannot distinguish infected child or maternal antibodies passed to the fetus through the placenta. Nevertheless, the so-called rapid tests have been implemented in the network of health services because of their simplicity and performance comparable to conventional tests. DPP HIV 1/2 test, produced by Bio-Manguinos/Fiocruz, usage is limited by the manufacturer to over 24 months of age children, though the guidelines control programs already recommend the use from 18 months in Brazil and 9 months in other countries. Data on the accuracy of the rapid test under 24 months of age are scarce. This proposal aims to assess the performance of rapid tests produced by Bio-Manguinhos in diagnostic protocols for HIV infection in children 9-24 months old, in order to obtain empirical data to support the current recommendations on rapid tests, particularly in countries with limited access to tests that require specialized laboratories. The validation of rapid HIV testing in other age groups is a requirement of the national regulatory authorities, and has important implications for programs to control HIV-AIDS in populations from countries with limited access to specialized laboratory resources. The use of the rapid test can also represent a significant reduction in costs, as it allows limiting the use of molecular tests to complex and expensive confirmation cases.

Condition or Disease	Intervention/Treatment	Phase
Human Immunodeficiency Virus Transmission Human Immunodeficiency Virus Diagnoses, Syndromes, and Conditions	Behavioral: This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years

Detailed Description

It concerns a study with a sample composed of children born from HIV positive mothers, age between 9 and 24 months old, with confirmed or discarded infection for HIV determined by molecular testing. Samples from the volunteers will be subjected to rapid tests and serological and molecular reference tests.

After obtaining consent from the child's guardian,a brief interview will take place with completing the questionnaire of inclusion in the research. Then, the collection of fluid in the oral cavity as well as the fingerstick puncture will be conducted for the HIV rapid tests procedures.

The results of the rapid tests will be compared with the ones from the molecular testing and the concordance will be determined for each age group separately.

The study has being conducted by four clinical research sites at Brazil, distributed in three different states, and a clinical research site at Tanzânia: Instituto Fernandes Figueira (IFF

Fiocruz) at Rio de Janeiro; Hospital Geral de Nova Iguaçu (HGNI) at Rio de Janeiro, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) at Amazonas; Secretaria de Estado de Saúde Pública do Pará (URES - Materno Infantil - UREMIA) at Pará and National Institute for Medical Research (NIMR) at Tanga in Tanzania.

Study Design

Study Type:

Observational

Anticipated Enrollment :

502 participants

Observational Model:

Case-Control

Time Perspective:

Cross-Sectional

Official Title:

Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children

Actual Study Start Date :

Mar 12, 2015

Anticipated Primary Completion Date :

Jun 5, 2020

Anticipated Study Completion Date :

Jul 31, 2020

Outcome Measures

Primary Outcome Measures

Efficacy of the Bio-Manguinhos / Fiocruz Rapid DPP® HIV-1/2 Immunoblot [Day 1]
Sensitivity and specificity of the Bio-Manguinhos / Fiocruz Rapid DPP® HIV-1/2 Immunoblot, based on the molecular test.

Secondary Outcome Measures

Efficacy of the Bio-Manguinhos / Fiocruz HIV-1/2 rapid serum screening test [Day 1]
Sensitivity and specificity of the Bio-Manguinhos / Fiocruz HIV-1/2 rapid serum screening test in children aged 9 to 24 months, using the Elisa or chemiluminescence and molecular test as reference.
Efficacy of the rapid Oral Fluid test HIV- 1/2 Bio- Manguinhos [Day 1]
Sensitivity and specificity of the rapid Oral Fluid test HIV- 1/2 Bio- Manguinhos in children ,taking as reference molecular testing.
Variations in the accuracy of rapid tests [Day 1]
Covariables of mothers and children

Eligibility Criteria

Criteria

Ages Eligible for Study:

9 Months to 24 Months

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Children must be born from a HIV infected mother; Molecular diagnostic tests available.

Exclusion Criteria:

Not applicable

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Assessoria Clinica / Bio-Manguinhos / Fiocruz	Rio De Janeiro		Brazil	21.040-360

Sponsors and Collaborators

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Conselho Nacional de Desenvolvimento Científico e Tecnológico